RS60650B1 - Farmaceutska formulacija koja sadrži inozitol - Google Patents

Farmaceutska formulacija koja sadrži inozitol

Info

Publication number
RS60650B1
RS60650B1 RS20200966A RSP20200966A RS60650B1 RS 60650 B1 RS60650 B1 RS 60650B1 RS 20200966 A RS20200966 A RS 20200966A RS P20200966 A RSP20200966 A RS P20200966A RS 60650 B1 RS60650 B1 RS 60650B1
Authority
RS
Serbia
Prior art keywords
inositol
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
RS20200966A
Other languages
English (en)
Inventor
Vittorio Unfer
Original Assignee
Lo Li Pharma Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lo Li Pharma Srl filed Critical Lo Li Pharma Srl
Publication of RS60650B1 publication Critical patent/RS60650B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5052Proteins, e.g. albumin
    • A61K9/5057Gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20200966A 2011-03-22 2012-03-22 Farmaceutska formulacija koja sadrži inozitol RS60650B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000445A ITMI20110445A1 (it) 2011-03-22 2011-03-22 Formulazione farmaceutica comprendente inositolo.
EP12160674.3A EP2502622B1 (en) 2011-03-22 2012-03-22 Pharmaceutical formulation comprising inositol

Publications (1)

Publication Number Publication Date
RS60650B1 true RS60650B1 (sr) 2020-09-30

Family

ID=43977111

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20200667A RS60377B1 (sr) 2011-03-22 2012-03-22 Farmaceutska formulacija koja sadrži inozitol
RS20200966A RS60650B1 (sr) 2011-03-22 2012-03-22 Farmaceutska formulacija koja sadrži inozitol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20200667A RS60377B1 (sr) 2011-03-22 2012-03-22 Farmaceutska formulacija koja sadrži inozitol

Country Status (22)

Country Link
US (1) US20140010870A1 (sr)
EP (2) EP3178474B1 (sr)
CL (1) CL2013002700A1 (sr)
CY (2) CY1122980T1 (sr)
DK (2) DK2502622T3 (sr)
EA (1) EA026746B1 (sr)
ES (2) ES2806937T3 (sr)
HR (2) HRP20200792T1 (sr)
HU (2) HUE051001T2 (sr)
IL (1) IL228465B (sr)
IT (1) ITMI20110445A1 (sr)
LT (2) LT2502622T (sr)
MA (1) MA35043B1 (sr)
ME (1) ME03750B (sr)
MX (1) MX2013010812A (sr)
PE (1) PE20141011A1 (sr)
PL (2) PL3178474T3 (sr)
PT (2) PT3178474T (sr)
RS (2) RS60377B1 (sr)
TN (1) TN2013000373A1 (sr)
UA (1) UA115425C2 (sr)
WO (1) WO2012126931A1 (sr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUA20163025A1 (it) 2016-04-29 2017-10-29 Sochim Int S P A Composizione per il trattamento della sindrome dell’ovaio policistico
US11040016B2 (en) * 2016-10-06 2021-06-22 Dy Natural Co., Ltd Composition for alleviating, preventing or treating female menopausal symptoms, containing, as active ingredient, pinitol, D-chiro-inositol or analog compounds thereof
US11898184B2 (en) 2017-09-07 2024-02-13 Sweet Sense Inc. Low glycemic sugar composition
US11484540B2 (en) * 2017-11-23 2022-11-01 Biosearch. S.A. Method for increasing embryo implantation rate in a female subject suffering polycystic ovary syndrome
WO2020039014A1 (en) * 2018-08-22 2020-02-27 Société des Produits Nestlé S.A. Composition comprising isomers of inositol and its use
EP4021429A1 (en) * 2019-08-30 2022-07-06 Société des Produits Nestlé S.A. Scyllo-inositol and b-cell mediated disorders
JP2022548560A (ja) * 2019-09-24 2022-11-21 ソシエテ・デ・プロデュイ・ネスレ・エス・アー scyllo-イノシトール及びインスリン増感剤としてのその使用
RU2757220C1 (ru) * 2020-06-03 2021-10-12 Общество с ограниченной ответственностью "ОКТАВА ХОЛДИНГ" Фармацевтическая композиция для профилактики и лечения синдрома поликистозных яичников
RU2771426C1 (ru) * 2021-05-03 2022-05-04 Румиса Рамзановна Бериханова Способ коррекции дислипидемии у женщин с метаболическим синдромом в периоде менопаузального перехода

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8305693D0 (en) * 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
JPH04504847A (ja) * 1989-03-08 1992-08-27 ザ ユニバーシティ オヴ バージニア パテント ファウンデーション インスリン抵抗性糖尿病のための食事用補添物
TW282398B (sr) * 1993-12-22 1996-08-01 Bristol Myers Squibb Co
EP1173188A2 (en) * 1999-04-27 2002-01-23 Insmed Pharmaceuticals, Inc. Pharmaceutical composition comprising an inositol and a metal ion for improving insulin sensitivity and glucose metabolism
EP1274459B1 (en) * 2000-04-19 2005-11-16 Genentech, Inc. Sustained release formulations comprising growth hormone
KR101156789B1 (ko) * 2004-07-30 2012-06-18 와쿠나가 세이야쿠 가부시키 가이샤 젤라틴 피막용 조성물, 젤라틴 피막, 및 이를 이용한 캡슐제
US20090149481A1 (en) * 2005-07-04 2009-06-11 Tokyo Medical And Dental University Pharmaceutical composition and beverage composition comprising l-arginine
US20070104801A1 (en) * 2005-11-07 2007-05-10 Ivf Online Llc Fertility and anti-aging supplement for the fertility health of females and males
CA2637806A1 (en) * 2005-11-07 2007-05-18 Russell M. Jaffe Compositions for regulating metabolic disorders and methods of use thereof
ITRM20070341A1 (it) * 2007-06-20 2008-12-21 Lo Li Pharma Srl Formulazione integrativa inofolic finalizzata al controllo dell'induzione dell'ovulazione in programmi di procreazione medicalmente assistita
WO2011112167A1 (en) * 2009-03-13 2011-09-15 Reset Therapeutics, Inc. Compositions and methods for diabetes treatment
SI2542224T1 (sl) * 2010-03-01 2014-10-30 Ratiopharm Gmbh Oralni farmacevtski sestavek, ki vsebuje dabigatran eteksilat

Also Published As

Publication number Publication date
EP3178474A1 (en) 2017-06-14
DK2502622T3 (da) 2020-09-07
IL228465A0 (en) 2013-12-31
RS60377B1 (sr) 2020-07-31
PT3178474T (pt) 2020-05-06
HUE051001T2 (hu) 2021-01-28
EA201301061A1 (ru) 2014-02-28
EP2502622A1 (en) 2012-09-26
EP2502622B1 (en) 2020-06-10
WO2012126931A1 (en) 2012-09-27
HUE049942T2 (hu) 2020-11-30
EA026746B1 (ru) 2017-05-31
MA35043B1 (fr) 2014-04-03
CL2013002700A1 (es) 2014-07-11
MX2013010812A (es) 2014-03-21
UA115425C2 (uk) 2017-11-10
PL2502622T3 (pl) 2020-11-16
HRP20201048T1 (hr) 2020-10-16
IL228465B (en) 2018-01-31
ES2798267T3 (es) 2020-12-10
DK3178474T3 (da) 2020-06-08
CY1122980T1 (el) 2021-10-29
PL3178474T3 (pl) 2020-09-21
LT3178474T (lt) 2020-05-11
CY1123134T1 (el) 2021-10-29
ITMI20110445A1 (it) 2012-09-23
US20140010870A1 (en) 2014-01-09
TN2013000373A1 (en) 2015-01-20
ME03750B (me) 2021-04-20
ES2806937T3 (es) 2021-02-19
PE20141011A1 (es) 2014-08-27
LT2502622T (lt) 2020-07-27
PT2502622T (pt) 2020-06-29
HRP20200792T1 (hr) 2020-07-24
EP3178474B1 (en) 2020-03-18

Similar Documents

Publication Publication Date Title
HRP20181896T1 (hr) Farmaceutske formulacije
HK1203812A1 (en) Novel pharmaceutical formulations
GB201111438D0 (en) Formulation
SG10201604667YA (en) Pharmaceutical preparation
IL228465B (en) Preparations containing inositol
GB201111439D0 (en) Formulation
HK1205146A1 (en) Pharmaceutical formulation
GB201105298D0 (en) Pharmaceutical preparation
EP2770828A4 (en) FORMULATION
PL2691119T3 (pl) Preparat farmaceutyczny
HK1209339A1 (en) Pharmaceutical formulations
HK1204945A1 (en) Pharmaceutical formulation containing flupirtin
GB201106958D0 (en) Formulation
GB201111577D0 (en) Pharmaceutical formulations
GB201211406D0 (en) Pharmaceutical formulations
GB201211403D0 (en) Pharmaceutical formulations
GB201104284D0 (en) Formulation